Results of the multicohort phase 1b ACTION trial indicated that anlotinib plus TQB2450 shows encouraging antitumor activity and tolerable toxicity in patients with recurrent advanced ovarian cancer. Read More ›

Findings of a national survey of US ovarian cancer programs identified several patient care deficits, including a greater need for the integration of palliative care, social work, dietetics, and financial counseling, and the expansion of clinical trials and genetic testing/counseling. Read More ›

Results of the C-MOnGene study support the adoption of a collaborative oncogenetic model that provides flexible, patient-centered, and efficient genetic counseling and testing for hereditary breast and ovarian cancer and serves as an example for other institutions to incorporate these aspects into their oncology care. Read More ›

Results from a retrospective analysis indicate that health education, using a clinical nursing pathway, results in a more effective understanding of ovarian cancer, reduced psychological burden, improved sleep quality, decreased incidence of complications, improved self-care agency, and improved quality of life among patients with ovarian cancer. Read More ›

The findings of a prospective study suggest that immunologic response to SARS-CoV-2 vaccination is lower among patients with ovarian cancer who are receiving treatment compared with healthy volunteers, indicating that such patients should maintain precautions against COVID-19 despite vaccination. Read More ›

This review outlines the disruptions to delivery of cancer care caused by the COVID pandemic, including delays in diagnosis, surgery, and treatment, as well as the psychological impact. Read More ›

Findings of a retrospective study indicate that patients with platinum-sensitive recurrent ovarian cancer were increasingly being administered maintenance therapy after second-line or third-line platinum-based chemotherapy regardless of biomarker status. Read More ›

Pooled analysis data from the PRIMA, NOVA, and NORA trials suggest that patients with BRCA-mutated ovarian cancer derive a significant progression-free survival benefit from niraparib maintenance treatment, with no new safety signals. Read More ›

Patient-reported outcomes of tolerability with adavosertib indicated greater incidence of fatigue, diarrhea, mucositis, and difficulty swallowing in patients receiving adavosertib and gemcitabine; however, no significant differences were noted in the symptomatic adverse-event profile for gastrointestinal events and anxiety. Read More ›

Results of the phase 1b FORWARD II trial show that the MIRV/bevacizumab combination demonstrates promising antitumor activity with durable responses and favorable tolerability in high FRα recurrent ovarian cancer. Read More ›

Page 1 of 3

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: